A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients with Paroxysmal

Administered By

Awarded By

Contributors

Start/End

  • May 12, 2021 - May 14, 2026